儿童急性淋巴细胞白血病微小残留病检测的临床意义
The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.
作者信息
Moppett J, Burke G A A, Steward C G, Oakhill A, Goulden N J
机构信息
Department of Paediatric Oncology and Haematology, Bristol Royal Hospital for Children, Bristol BS2 8JD, UK.
出版信息
J Clin Pathol. 2003 Apr;56(4):249-53. doi: 10.1136/jcp.56.4.249.
Abstract
Risk directed treatment forms a central component of modern protocols for childhood acute lymphoblastic leukaemia (ALL). A review of recent studies of minimal residual disease (MRD) analysis shows that it is a powerful prognostic factor in both first line and relapse treatment. However, the value of MRD analysis is both time point and protocol specific, and the threshold for MRD detection of the technique used impacts upon the results obtained. MRD analysis does have a useful role to play in the risk directed treatment of childhood ALL, and this is currently being investigated in large prospective studies.
摘要
风险导向治疗是现代儿童急性淋巴细胞白血病（ALL）治疗方案的核心组成部分。对近期微小残留病（MRD）分析研究的综述表明，它在一线治疗和复发治疗中都是一个强大的预后因素。然而，MRD分析的价值既取决于时间点，也因方案而异，所使用技术的MRD检测阈值会影响所得结果。MRD分析在儿童ALL的风险导向治疗中确实具有重要作用，目前大型前瞻性研究正在对此进行调查。
相似文献
1
The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.
J Clin Pathol. 2003 Apr;56(4):249-53. doi: 10.1136/jcp.56.4.249.
2
Risk-adapted treatment according to minimal residual disease in adult ALL.
Best Pract Res Clin Haematol. 2002 Dec;15(4):639-52. doi: 10.1053/beha.2002.0229.
3
Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Br J Haematol. 2011 Mar;152(6):743-53. doi: 10.1111/j.1365-2141.2010.08456.x. Epub 2011 Jan 20.
4
Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
Br J Haematol. 2014 May;165(3):392-401. doi: 10.1111/bjh.12749. Epub 2014 Jan 30.
5
[Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
Zhonghua Er Ke Za Zhi. 2010 Mar;48(3):180-4.
6
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
Lancet. 1998 Nov 28;352(9142):1731-8. doi: 10.1016/S0140-6736(98)04058-6.
7
Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Br J Haematol. 2015 Feb;168(3):395-404. doi: 10.1111/bjh.13142. Epub 2014 Oct 14.
8
Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia.
Br J Haematol. 2011 Oct;155(1):45-52. doi: 10.1111/j.1365-2141.2011.08795.x. Epub 2011 Aug 4.
9
Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.
Br J Haematol. 2003 Jul;122(1):24-9. doi: 10.1046/j.1365-2141.2003.04394.x.
10
[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
Klin Padiatr. 2000 Jul-Aug;212(4):169-73. doi: 10.1055/s-2000-9672.
引用本文的文献
1
The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
Int J Mol Sci. 2024 Apr 30;25(9):4881. doi: 10.3390/ijms25094881.
2
Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.
Eur J Haematol. 2020 Apr;104(4):299-309. doi: 10.1111/ejh.13375. Epub 2020 Jan 24.
3
Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.
Ont Health Technol Assess Ser. 2016 Mar 8;16(7):1-52. eCollection 2016.
4
SVSI: fast and powerful set-valued system identification approach to identifying rare variants in sequencing studies for ordered categorical traits.
Ann Hum Genet. 2015 Jul;79(4):294-309. doi: 10.1111/ahg.12117. Epub 2015 May 11.
5
Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study.
Med Oncol. 2014 May;31(5):938. doi: 10.1007/s12032-014-0938-z. Epub 2014 Apr 2.
6
A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.
Pediatr Blood Cancer. 2009 Dec;53(6):978-83. doi: 10.1002/pbc.22209.
7
A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Haematologica. 2009 Jun;94(6):781-9. doi: 10.3324/haematol.2008.003137.
8
Minimal metastatic disease.
J Clin Pathol. 2004 Jan;57(1):21. doi: 10.1136/jcp.57.1.21.
本文引用的文献
1
The study of minimal residual disease in acute lymphoblastic leukaemia.
Clin Mol Pathol. 1995 Apr;48(2):M65-73. doi: 10.1136/mp.48.2.m65.
2
EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.
Cancer Chemother Rep. 1964 Feb;35:1-111.
3
Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.
Leukemia. 2002 Sep;16(9):1668-72. doi: 10.1038/sj.leu.2402552.
4
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
Cancer Cell. 2002 Mar;1(2):133-43. doi: 10.1016/s1535-6108(02)00032-6.
5
Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.
Blood. 2002 Jul 1;100(1):52-8. doi: 10.1182/blood-2002-01-0006.
6
A competitive PCR-based method using TCRD, TCRG and IGH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia.
Leukemia. 2002 Apr;16(4):762-4. doi: 10.1038/sj.leu.2402396.
7
Childhood acute lymphoblastic leukaemia--current status and future perspectives.
Lancet Oncol. 2001 Oct;2(10):597-607. doi: 10.1016/S1470-2045(01)00516-2.
8
5' CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia.
Blood. 2002 Apr 1;99(7):2291-6. doi: 10.1182/blood.v99.7.2291.
9
Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.
Blood. 2002 Mar 15;99(6):1952-8. doi: 10.1182/blood.v99.6.1952.
10
Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome.
Blood. 2002 Feb 15;99(4):1253-8. doi: 10.1182/blood.v99.4.1253.
Zotero 插件